BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
The order will cover the manufacturing of bulk vaccine in 2026
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Subscribe To Our Newsletter & Stay Updated